Making strange or making sense - art and the life sciences
07 April, 2005 by Oron Catts and Ionat ZurrOron Catts and Ionat Zurr talk about the future with Bioart.
In brief: Benitec, XRT, Phylogica, Norwood Abbey
06 April, 2005 by Staff WritersRNAi specialist Benitec (ASX:BLT) has lodged a prospectus with ASIC to raise up to AUD$9.7 million in a rights issue, underwritten by Bell Potter. Capital raised will go towards clinical development and expansion of Benitec's California operations, it said.
Research prospective
05 April, 2005 by Nigel PooleNigel Poole offers 10 glimpses of what Australian life science commercialisation could look like in 2015.
Can life sciences go the IT way?
05 April, 2005 by Prashant TyagiThe life sciences can learn from the IT revolution, Prashant Tyagi explains.
Legal Challenges
05 April, 2005 by Trevor DaviesWith technology advancing so rapidly in many potential commercial areas of life science, patent attorneys, intellectual property (IP) and commercial lawyers, and lawmakers will face a number of challenges over the next 10 years, says Trevor Davies.
In brief: changes at Psiron, ATPi, Cytopia, Epitan
04 April, 2005 by Renate KrellePsiron (ASX:PSX) has announced that Stephen Jones will assume day-to-day control of the company, taking on the role of executive chairman. Julie Nutting will continue as the company's chief executive with responsibility for five clinical trial and manufacturing milestones for the company's CVA 21 virus by the end of the year.
Biotech students band together
01 April, 2005 by Melissa TrudingerThe South Australian branch of the AusBiotech Student Association (ABSA) was launched last night in Adelaide.
In brief: Resonance Health; Covance
24 March, 2005 by Staff WritersAustralia's largest diagnostic imaging company, DCA Group (ASX: DVC) has agreed to launch and co-market Resonance Health's (ASX:RHT) liver diagnostic, FerriScan in Australia and potentially the UK.
First biosciences company lists in Singapore
23 March, 2005 by Renate KrelleDutch company LMA International has become the first biosciences company to list on Singapore's stock exchange, raising S$248 million (AUD$194 million) through the an initial public offering by its Singapore unit, LMA International.
GBS invests in US-based biotech
23 March, 2005 by Melissa TrudingerAustralian biotech venture capitalists GBS Venture Partners has invested in US-based therapeutic antibody company KaloBios Pharmaceuticals as part of a US$20 million series B financing round.
Domantis in licence deal with Tanox
23 March, 2005 by Renate KrelleUK biotech Domantis -- in which Sydney firm Peptech (ASX:PTD) is a 36 per cent investee -- has licensed the rights to domain antibodies for a specific but undisclosed autoimmune target to US biotech Tanox, best known for its asthma biological Xolair.
Teaching Australia's future life scientists
22 March, 2005 by Kathy TakayamaA change is needed in the way science is taught, argues Kathy Takayama.
Trends in teaching hospital laboratories
22 March, 2005 by Ross ViningOver the next decade two powerful forces, economics and technology, will reshape teaching hospital laboratories, writes Ross Vining.
The art of science
22 March, 2005 by Susan WilliamsonMiranda Grounds spoke with Susan Williamson about how art is helping to drive things forward in science.
The new gods: ethics in the next decades
22 March, 2005 by Julian Savulescu and Bennett FoddyEthics need to change radically to keep up with technology, write Julian Savulescu and Bennett Foddy.
